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Extracellular adenosine is a neuromodulator in the central nervous system. Astrocytes mainly participate
in adenosine production, and extracellular adenosine accumulates under physiological and pathophys-
iological conditions. Inhibition of intracellular adenosine metabolism and reduction of the external Ca2þ
concentration ([Ca2þ]e) participate in adenosine accumulation, but the precise mechanisms remain
unclear. This study investigated the mechanisms underlying extracellular adenosine accumulation in
cultured rat spinal astrocytes. The combination of adenosine kinase and deaminase (ADK/ADA) inhibition
and a reduced [Ca2þ]e increased the extracellular adenosine level. ADK/ADA inhibitors increased the level
of extracellular adenosine but not of adenine nucleotides, which was suppressed by inhibition of equi-
librative nucleoside transporter (ENT) 2. Unlike ADK/ADA inhibition, a reduced [Ca2þ]e increased the
extracellular level not only of adenosine but also of ATP. This adenosine increase was enhanced by ENT2
inhibition, and suppressed by sodium polyoxotungstate (ecto-nucleoside triphosphate diphosphohy-
drolase inhibitor). Gap junction inhibitors suppressed the increases in adenosine and adenine nucleotide
levels by reduction of [Ca2þ]e. These results indicate that extracellular adenosine accumulation by ADK/
ADA inhibition is due to the adenosine release via ENT2, while that by reduction of [Ca2þ]e is due to
breakdown of ATP released via gap junction hemichannels, after which ENT2 incorporates adenosine into
the cells.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
In the central nervous system (CNS), astrocytes produce aden-
osine, which plays an important role as a neuromodulator (1).
Adenosine is transported across cellular membrane via adenosine
gradient-dependent equilibrative nucleoside transporter (ENT); in
particular, ENT1 and ENT2 reportedly play amajor role in adenosine
transport in the CNS (2,3). ENT1 is sensitive to low concentrations
of S-(4-nitrobenzyl)-6-thioinosine (NBTI) (4), while higher con-
centrations of NBTI and dipyridamole (DIP) are necessary to inhibit
ENT2 (2). The intracellular adenosine level is thought to be kept low
owning to the conversion of adenosine into AMP and inosine via.-i. Otsuguro).
rmacological Society.
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d/4.0/).adenosine kinase (ADK) and adenosine deaminase (ADA), respec-
tively (5). On the other hand, astrocytes reportedly release ATP by
exocytosis (6) and gap junction hemichannels (7,8), which is in turn
broken down to adenosine via a series of ecto-enzymes including
ecto-nucleoside triphosphate diphosphohydrolases (ecto-NTPDa-
ses) and ecto-5’-nucleotidase (9). Thereafter, adenosine is incor-
porated into cells by nucleoside transporters (NTs). Thus, the
analysis of not only adenosine but also of adenine nucleotides is
often important to reveal the mechanisms underlying adenosine
accumulation.
Inhibition of intracellular adenosine metabolism reportedly in-
duces extracellular adenosine accumulation under hypoxic/
ischemic conditions owing to an increased intracellular concen-
tration of adenosine in the brain and spinal cord (10e12). In rat
hippocampus, ENT1 and/or ENT2 are reportedly responsible for
adenosine efﬂux upon ADK inhibition (13).
On the other hand, reduction of the external Ca2þ concentration
([Ca2þ]e) also causes adenosine accumulation in rat brain (14e16).nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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However, experimental Ca2þ-free conditions, in which Ca2þ is
replaced with Mg2þ, are suspected to induce the release of aden-
osine by inhibiting intracellular adenosine metabolism because
Mg2þ can inhibit ADK activities (18,19). Therefore, the mechanisms
underlying adenosine accumulation by reduction of [Ca2þ]e remain
unclear.
In the spinal cord, it was reported that adenosine mediates
antinociceptive and neuroprotective effects via adenosine re-
ceptors (20,21). The astrocytic turnover of adenosine and adenine
nucleotides has beenwell-documented in brain but not spinal cord.
Therefore, we investigated the mechanisms underlying adenosine
accumulation by inhibition of intracellular adenosine metabolic
enzymes and reduction of [Ca2þ]e in cultured astrocytes of rat
spinal cord via high-performance liquid chromatography (HPLC)
and luciferin/luciferase method.
2. Materials and methods
2.1. Spinal astrocyte cultures
All animal care and experimental protocols were approved by
the Committee on Animal Experimentation, Graduate School of
Veterinary Medicine, Hokkaido University (No. 13020/13-0029).
Every effort was made to minimize animal suffering and to reduce
the number of animals used.
Primary cultures of spinal astrocytes were obtained fromWistar
rats (0e3 days old, Clea Japan, Tokyo, Japan). Neonatal rats were
killed by decapitation and the isolated spinal cord was minced in
divalent cation-free Hanks' balanced salt solution. Following
digestion with papain (10 U/ml) and DNase (0.1 mg/ml) at room
temperature for 20min, tissues weremechanically dissociatedwith
a Pasteur pipette in culture medium. The culture medium was
Dulbecco's Modiﬁed Eagle Medium (DMEM)-F12 containing 10%
fetal bovine serum, 100 U/ml penicillin, and 0.1 mg/ml of strepto-
mycin. Thereafter, the cell suspension was transferred to a poly-L-
lysine-coated T75 ﬂask, and the medium was replaced after 1e2 h.
Cells were cultured in a humidiﬁed environment containing 5% CO2
at 37 C and fed every 2 or 3 days with new medium. When cells
reached 80e90% conﬂuency, ﬂasks were shaken vigorously at
250 rpm for at least 12 h to remove all cells except for astrocytes.
The remaining astrocytes were trypsinized and seeded into poly-L-
lysine-coated 6-well plates. Cells were used for experiments after
they had reached conﬂuency. Almost all cells were positive for the
astrocyte marker glial ﬁbrillary acidic protein (GFAP) (Fig. S1). All
cultured astrocytes were used within 3 weeks of isolation.
2.2. Extracellular purine assay
Astrocyte cultures in 6-well plates were incubated with 1 ml of
artiﬁcial cerebrospinal ﬂuid (ACSF). After the mediumwas changed,
the amount of extracellular adenosine increased, peaked at
approximately 20 min, and was maintained at this level for 2 h
(Fig. S2). Therefore, to examine the effects of ADK and ADA in-
hibitors, we pre-incubated cells with ACSF for at least 1 h unless
otherwise noted. Thereafter, drugs were directly added from stocks
to each well without changing the medium, and the culture plates
were gently rotated several times. To examine the effects of a
reduced [Ca2þ]e, astrocyte cultures were incubated with nominal
Ca2þ-free ACSF, for 1 h in most experiments. Gap27 and 10Panx1
were pretreated with normal ACSF for 30 min. After collecting a
sample (500 ml), cells were suspended in 0.1 N NaOH and sonicated.
The protein content of cell lysates was measured using the Quick
Start protein assay (Bio-Rad, Hercules, CA, USA). The composition of
ACSF was as follows: 138 mM NaCl, 3.5 mM KCl, 1.25 mM CaCl2,1.2 mM MgCl2, 25 mM HEPES, and 10 mM glucose (pH 7.3 with
NaOH). To reduce [Ca2þ]e, CaCl2 in ACSF was replaced with equi-
molar MgCl2.2.3. Measurement of purines by HPLC analysis
The purines (adenosine, AMP, ADP, and ATP) in the collected
samples were eteno-derivatized according to a previously
described method (22). The concentrations of ethenoderivatives of
purines were determined by reverse-phase HPLC with an Accucore
aQ column (4.6 150mm, ThermoFisher Scientiﬁc, Tokyo, Japan) at
45 C and a ﬂuorescence detector (FP-540D, Nihon Koden, Tokyo,
Japan). The mobile phase buffer consisted of 100 mM KH2PO4,
5 mM tetrabutylammonium bromide, and 2.0% CH3CN (pH 3.3 with
H3PO4). The ﬂow rate was 0.8 ml/min. The detection limits were
about 2 nM for adenosine, AMP, and ADP, and about 10 nM for ATP.
The amounts of purines were expressed as the extracellular amount
per milligram of protein content in cell lysates (pmol/mg or nmol/
mg).2.4. Measurement of ATP by luciferin/luciferase analysis
After boiling, the collected sample was chilled on ice, and the
concentration of ATP was determined by luciferin/luciferase assay
using the ATP Determination Kit (Invitrogen, Carlsbad, CA, USA)
with a microplate reader (SH-9000 Lab, Corona Electric, Hitachi-
naka, Japan). The detection limit for ATP was about 1 nM.2.5. RT-PCR
The oligonucleotide primers used to amplify ENT, ecto-NTPDase,
connexin 43 (Cx43) and pannexin (Panx) are listed in Table S1. Total
RNA was extracted from cultured spinal astrocytes and the brain of
rats using TRI Reagent (SigmaeAldrich, St. Louis, MO, USA). First-
strand cDNA was synthesized and subsequently ampliﬁed using
ReverTra Ace (TOYOBO, Osaka, Japan) with Oligo(dT)20 primer and
Taq DNA polymerase (Promega, Tokyo, Japan), respectively.
Ampliﬁcation products were separated and analyzed by electro-
phoresis of 2.0% agarose gels containing ethidium bromide, and
visualized under ultraviolet light.2.6. Drugs
ABT-702 dihydrochloride, adenosine, AMP sodium salt, ATP
disodium salt, ARL67156 trisodium salt, carbenoxolone disodium
salt, dipyridamole (DIP), S-(4-nitrobenzyl)-6-thioinosine (NBTI),
a,b-methylene ADP sodium salt, meﬂoquine hydrochloride, bril-
liant blue G and A438079 were purchased from SigmaeAldrich.
ADP disodium salt was from Wako Pure Chemical (Osaka, Japan).
Erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA) and
sodium polyoxotungstate (POM-1) were from Tocris (Bristol, UK).
Flufenamic acid was from LKT Laboratories Inc. (St. Paul, MN, USA).
Gap27 and 10Panx1 were synthesized by Invitrogen (Tokyo, Japan).2.7. Data analysis
Each experiment was performed in at least three different cul-
tures. Results are expressed as mean ± SEM. Two groups were
statistically compared using the unpaired Student's t-test. For
multiple comparisons, ANOVA with Dunnett's test was used. A p
value of less than 0.05 was considered signiﬁcant.
Fig. 1. Inhibition of adenosine metabolic enzymes releases adenosine through ENT2.
(A) The increase in the extracellular adenosine level by ABT-702 treatment (0.1e10 mM)
in the presence or absence of EHNA (10 mM) for 30 min. *p < 0.05 versus ABT-702
(Student's t-test), n ¼ 8e10. (B) RT-PCR analysis of mRNA expression of ENT1, ENT2
and b-actin (b-a) in spinal astrocytes. Samples without reverse transcriptase were
considered as negative controls (NC). (C) Effects of ENT inhibitors on the adenosine
level. Spinal astrocytes were incubated for 30 min with ABT-702 (0.1 mM) or ABT-702
(1 mM)/EHNA (10 mM) in the presence of NBTI (100 nM) or NBTI (5 mM)/DIP (10 mM).
*p < 0.05 versus vehicle (Dunnett's test), n ¼ 12e14.
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3.1. Extracellular adenosine accumulation by inhibition of
adenosine metabolic enzymes
We ﬁrst examined the effects of inhibitors of adenosine meta-
bolic enzymes, ADK and ADA, on the adenosine level. ABT-702, an
ADK inhibitor, tended to increase the extracellular adenosine level
in a concentration-dependent manner (Fig. 1A). EHNA (10 mM), an
ADA inhibitor, alone had little effect on the adenosine level. How-
ever, in the presence of EHNA, ABT-702 markedly increased the
level of adenosine, but not that of AMP (control: 12.4 ± 3.3 pmol/
mg, ABT-702/EHNA: 10.1 ± 3.5 pmol/mg, n ¼ 10). In HPLC analysis,
levels of ADP and ATP were below the detection limit after 30 min-
incubation, regardless of the presence or absence of ABT-702/
EHNA. Luciferin/luciferase analysis showed that ABT-702/EHNA
had no effect on the ATP level (control: 2.8 ± 0.7 pmol/mg, ABT-
702/EHNA: 2.2 ± 0.7 pmol/mg, n ¼ 12).
RT-PCR analysis revealed that rat spinal astrocytes expressed
ENT1 and ENT2 (Fig. 1B). After pre-incubationwith normal ACSF for
1 h, treatment with a low concentration (100 nM) of NBTI for
30 min signiﬁcantly increased the adenosine level (Fig. 1C). A
mixture of NBTI (5 mM) and DIP (10 mM) (NBTI/DIP) did not further
increase the adenosine level. ABT-702 (0.3 mM) increased the
adenosine level, which was not affected by NBTI and NBTI/DIP. ABT-
702/EHNA greatly enhanced the increase in the adenosine level,
which was suppressed by NBTI/DIP but not by NBTI alone.
3.2. Extracellular adenosine accumulation by reduction of the
external Ca2þ concentration
Mg2þ reportedly inhibits ADK activity (18,19). We then incu-
bated cells in ACSF containing various concentrations of Ca2þ and/
or Mg2þ for 1 h (Fig. 2). Regardless of the presence or absence of
Mg2þ, the extracellular adenosine level markedly increased in the
absence of Ca2þ.
Unlike the effects of ABT-702/EHNA, a decreased Ca2þ concen-
tration in ACSF increased the level not only of adenosine but also of
adenine nucleotides, but did not greatly change the ratio of aden-
osine to adenine nucleotides (Fig. 3A). Purine accumulation in
Ca2þ-free ACSF was signiﬁcantly enhanced by NBTI/DIP but not by
NBTI alone (Fig. 3B). NBTI/DIP enhanced the increase in the level of
adenosine but not that of adenine nucleotides.Fig. 2. Removal of extracellular Ca2þ increases the adenosine level. The extracellular
concentrations (mM) of Ca2þ ([Ca2þ]e) and Mg2þ ([Mg2þ]e) were changed. **p < 0.01
versus 1.25 mM [Ca2þ]e and 1.2 mM [Mg2þ]e (Dunnett's test), n ¼ 9e18.
Fig. 3. ENT2 incorporates adenosine that is increased by changing the solution to
Ca2þ-free ACSF. (A) Ca2þ concentration-dependence of purine levels. The extracellular
concentration of Ca2þ ([Ca2þ]e) was changed, and spinal astrocytes were incubated for
1 h **p < 0.01 versus 1.25 mM [Ca2þ]e (Dunnett's test), n ¼ 9. (B) Effect of ENT inhi-
bition on the increase in purine levels evoked by changing the solution to Ca2þ-free
ACSF. Spinal astrocytes were incubated for 1 h with Ca2þ-free ACSF containing NBTI
(100 nM) or NBTI (5 mM)/DIP (10 mM). *p < 0.05, **p < 0.01 versus Ca2þ-free (Dunnett's
test), n ¼ 10. ADO, adenosine.
Fig. 4. Ecto-NTPDase contributes to the increase in the adenosine level evoked by
changing the solution to normal ACSF and Ca2þ-free ACSF. (A) Effect of ecto-NTPDase
inhibitors on purine levels in normal ACSF and Ca2þ-free ACSF. Spinal astrocytes were
incubated for 1 h with normal ACSF or Ca2þ-free ACSF containing ARL67156 (ARL,
50 mM) or POM-1 (100 mM), n ¼ 8e14. (B) RT-PCR analysis of mRNA expression of ecto-
NTPDase (ENTPD) 1e3 and b-actin (b-a) in spinal astrocytes. Samples without reverse
transcriptase were considered as negative controls (NC). Rat brain cDNA was used as a
positive control for ENTPD3. ADO, adenosine.
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total purine accumulation and the ratio of purine (Fig. 4A and
Table 1). Another ecto-NTPDase inhibitor, POM-1 (100 mM), also
had no effect on total purine accumulation but signiﬁcantly
increased the levels of ATP and ADP in normal and Ca2þ-free ACSF,
which was accompanied by a decrease in the adenosine level,
indicating the contribution of ATP release and its subsequent
breakdown to the increased adenosine level. RT-PCR analysis
conﬁrmed that rat spinal astrocytes expressed NTPDase1 and 2
(Fig. 4B).
3.3. Gap junction hemichannels contribute to ATP release
The time course of purine levels in normal and Ca2þ-free ACSF
was examined. Just after changing the solution to normal ACSF, ATP,ADP, and AMP, but not adenosine, were detectable. The levels of
these adenine nucleotides decreased exponentially andwere low at
1 h (Fig. 5), indicative of nucleotide release in response to the so-
lution change. Changing the solution to Ca2þ-free ACSF greatly
increased the amount of ATP, which peaked at around 1 min, and
decreased exponentially thereafter. The levels of ADP and AMP just
after changing the solution to Ca2þ-free ACSF were not different
from those in normal ACSF. However, in Ca2þ-free ACSF, these levels
peaked at around 10 min and gradually decreased thereafter. By
contrast, the adenosine level was extremely low just after changing
the solution to Ca2þ-free ACSF and then gradually increased,
peaking at around 1 h.
Cultured rat spinal astrocytes expressed Cx43 and Panx1 mRNA
(Fig. 6A). The non-selective gap junction inhibitors carbenoxolone
(10 mM), meﬂoquine (10 mM), and ﬂufenamic acid (100 mM)
inhibited the increase in total purines in Ca2þ-free ACSF, but not in
normal ACSF (Fig. 6B). Next, we measured the levels of adenine
nucleotides and adenosine for 10-min incubation with normal or
Ca2þ-free ACSF in the presence of selective gap junction inhibitors.
The respective connexin and pannexin inhibitors, Gap27 and
10Panx1, inhibited the increase in the total purine level in Ca2þ-free
ACSF (Fig. 6C). However, simultaneous treatment with Gap27 and
Table 1
Effects of ecto-NTPDase inhibitors on purine levels.
ADO AMP ADP ATP
Normal 77.6 ± 4.2 (385.3 ± 55.8) 13.8 ± 2.1 (66.8 ± 15.3) 7.7 ± 2.3 (38.1 ± 14.6) 0.9 ± 0.1 (3.5 ± 0.4)
Normal þ ARL 83.8 ± 2.0 (341.7 ± 35.1) 10.6 ± 1.4 (41.5 ± 5.7) 4.8 ± 0.7 (18.3 ± 2.4) 0.8 ± 0.1 (3.3 ± 0.4)
Normal þ POM-1 60.0 ± 2.5## (305.9 ± 25.4) 9.8 ± 1.2 (51.9 ± 9.1) 18.6 ± 1.9## (93.8 ± 11.2#) 11.6 ± 0.4## (58.9 ± 4.5##)
Ca2þ-free 85.6 ± 1.7 (2240.4 ± 290.6) 10.2 ± 1.5 (229.0 ± 31.6) 3.2 ± 0.3 (78.9 ± 12.0) 1.0 ± 0.2 (24.2 ± 3.4)
Ca2þ-free þ ARL 84.0 ± 2.0 (1985.4 ± 248.3) 11.4 ± 1.7 (223.4 ± 28.1) 3.3 ± 0.4 (69.2 ± 9.3) 1.2 ± 0.2 (24.8 ± 3.5)
Ca2þ-free þ POM-1 52.6 ± 2.8** (1369.9 ± 195.1*) 9.1 ± 1.1 (203.4 ± 23.1) 21.3 ± 1.1** (524.7 ± 67.0**) 17.1 ± 1.3** (410.4 ± 49.7**)
Each value is mean ± SEM. The ratio to the total purine level (%) is shown, together with the total amount of purines (pmol/mg) in parentheses. *p < 0.05, **p < 0.01 versus
Ca2þ-free (Dunnett's test). #p < 0.05, ##p < 0.01 versus normal (Dunnett's test), n ¼ 8e14. Medium was changed to normal artiﬁcial cerebrospinal ﬂuid (ACSF) or Ca2þ-free
ACSF containing ARL67156 (ARL, 50 mM) or sodium polyoxotungstate (POM-1, 100 mM), and then cells were incubated for 1 h. ADO, adenosine; ecto-NTPDase, ecto-nucleoside
triphosphate diphosphohydrolase.
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and 10Panx1 had no effect on the total purine level in normal ACSF.
Panx1 reportedly forms a complex with P2X7 receptors (23). The
P2X7 receptor antagonists brilliant blue G (10 mM) and A438079
(10 mM) slightly inhibited the increase in the total purine level in
normal or Ca2þ-free ACSF (Fig. S3).4. Discussion
The present study shows that inhibition of adenosine metabolic
enzymes and reduction of [Ca2þ]e increase the extracellular aden-
osine level in rat cultured spinal astrocytes. Inhibition of ADK and/
or ADA increases extracellular adenosine levels in various regions of
the CNS. As the intracellular adenosine level is kept low by ADK and
ADA, the inhibition of these enzymes increases the intracellular
adenosine, which in turn is transported into extracellular spaces
(10e12). However, in cultured rat spinal astrocytes, the extracel-
lular adenosine level was slightly increased by an ADK inhibitor but
not an ADA inhibitor, and was synergistically increased by a com-
bination of both inhibitors. These results suggest that, in spinalFig. 5. The time course of ATP (A), ADP (B), AMP (C), and adenosine (D) levels in
normal ACSF and Ca2þ-free ACSF. Spinal astrocytes were incubated with normal ACSF
or Ca2þ-free ACSF for 10 s or 1, 10, 30, 60, or 120 min *p < 0.05, **p < 0.01 versus
normal ACSF (Student's t-test), n ¼ 8e9.astrocytes, a main pathway for adenosine turnover is the phos-
phorylation of adenosine to AMP, that cytosolic adenosine is greatly
broken down to inosine by ADA when its level is increased upon
ADK inhibition, and that intracellular adenosine is released into the
extracellular space when its level is increased upon ADK and/or
ADA inhibition. In rat hippocampal slices, at least half of the
adenosine efﬂux by ADK inhibition is reportedly mediated via ENTs
(13). Astrocytes are thought to constantly release ATP, which is
again incorporated into cells by NTs after breakdown to adenosine.
In this study, a low concentration of NBTI increased the extracel-
lular adenosine level in resting conditions, suggesting that adeno-
sine inﬂux is associated with ENT1. However, the increased
adenosine efﬂux by an ADK inhibitor alone was not affected by ENT
inhibition. It seems likely that adenosine inﬂux is balanced by its
efﬂux under this condition. ADK and ADA inhibition elicited a great
increase in the extracellular adenosine level, which was inhibited
by NBTI/DIP. When the intracellular adenosine level is greatly
increased, it is suggested to be transported into the extracellular
space by ENT2, which has a low afﬁnity and a high capacity for
adenosine transport (24).
Reduction of [Ca2þ]e increased the extracellular adenosine level.
Mg2þ is often used to replace Ca2þ for experimental Ca2þ-free
conditions (15,16). Mg2þ reportedly inhibits ADK activities (18,19).
However, in the present study, adenosine accumulation induced by
Ca2þ-free ACSF was not affected regardless of the presence or
absence of Mg2þ, indicating that inhibition of adenosine meta-
bolism by Mg2þ is not associated with adenosine accumulation in
Ca2þ-free ACSF. Ischemia reduces [Ca2þ]e to approximately 0.1 mM
in the brain (17), which was sufﬁcient to cause adenosine accu-
mulation in spinal astrocytes in the present study. These results
suggest that reduction of [Ca2þ]e is an important factor for extra-
cellular adenosine accumulation during ischemia.
In this study, NBTI/DIP increased the adenosine level in Ca2þ-
free ACSF, suggesting the involvement of ENT2 to the uptake of
adenosine. It is likely that the increased adenosine level in Ca2þ-
free ACSF is due to adenine nucleotides released from astrocytes,
which are broken down to adenosine by a series of ecto-enzymes
including ecto-NTPDases. NTPDase 1e3 and 8 are reportedly
membrane-bound ecto-enzymes with ATP- and/or ADP-
hydrolyzing activity (9). Our study showed that rat spinal astro-
cytes expressed NTPDase1 and 2, and that POM-1, but not
ARL67156, signiﬁcantly increased the levels of ATP and ADP
concomitant with a decrease in that of adenosine. Similarly, in rat
cerebellar slices, the inhibitory effect of ARL67156 on ATP break-
down is weaker than that of POM-1 (25). Moreover, ARL67156
reportedly inhibits NTPDase1 and 3, POM-1 inhibits NTPDase1, 2,
and 3 (26), and NTPDase2 is a predominant subtype in rat brain
astrocytes (27). Taken together, it is suggested that NTPDase2 is
mainly responsible for hydrolysis of ATP in rat spinal astrocytes.
The time course of adenine nucleotide and adenosine accumu-
lation in response to solution change to normal or Ca2þ-free ACSF
Fig. 6. The removal of extracellular Ca2þ releases ATP through gap junction hemi-
channels. (A) RT-PCR analysis of mRNA expression of Cx43, Panx1, Panx2, and b-actin
(b-a) in spinal astrocytes. cDNA without reverse transcriptase was considered as a
negative control (NC). Rat brain cDNA was used as positive control of Panx2. (B) Effects
of non-selective gap junction inhibitors on purine levels. Spinal astrocytes were
incubated for 1 h with normal ACSF or Ca2þ-free ACSF containing CBX (10 mM), MFQ
(10 mM), or FFA (100 mM). *p < 0.05, **p < 0.01 versus Ca2þ-free ACSF (Dunnett's test),
n ¼ 8e9. (C) Effects of Gap27 and 10Panx1 on purine levels at 10 min in normal ACSF
and Ca2þ-free ACSF. Spinal astrocytes were pre-incubated for 30 min with normal ACSF
containing Gap27 (50 mM) or 10Panx1 (50 mM), and then incubated for 10 min with
normal ACSF or Ca2þ-free ACSF containing these inhibitors. *p < 0.05, **p < 0.01 versus
Ca2þ-free ACSF (Dunnett's test), n ¼ 9e11. CBX, carbenoxolone; MFQ, meﬂoquine; FFA,
ﬂufenamic acid.
R. Eguchi et al. / Journal of Pharmacological Sciences 128 (2015) 47e5352showed a great difference among purines. Although, just after
changing the solution, the amount of ATP was higher in Ca2þ-free
ACSF than in normal ACSF, the amounts of ADP and AMP were the
same in both types of ACSF. This is indicative of the release of
adenine nucleotides upon changing the solution per se. On the
other hand, adenosine accumulation occurred 10 min after the
solution change, suggesting the production of adenosine. The time
course of adenine nucleotide elimination seems to be exponential;
therefore, it is likely that the released ATP is broken down into ADP
or AMP by ecto-NTPDase, after which AMP is broken down to
adenosine by ecto-5’-nucleotidase.
In astrocytes, there are reportedly several pathways for ATP
release such as exocytosis (6) and gap junction hemichannels (7,8).
Exocytotic release of ATP by reduction of [Ca2þ]e is unlikely because
this process generally depends on Ca2þ. Non-selective gap junction
inhibitors inhibited the increase in purine levels in Ca2þ-free ACSF,
suggesting that gap junction hemichannels contribute to the ATP
release. Our data showed that rat spinal astrocytes expressed Cx43
and Panx1, and that selective connexin and pannexin inhibitors
inhibited the increase in purine levels in Ca2þ-free ACSF. Although
Cx43 and Panx1 both seemed to be responsible for ATP release,
simultaneous treatment with Gap27 and 10Panx1 did not show any
additive effect (data not shown). Cx43 hemichannels reportedly
open in response to reduction of [Ca2þ]e, whereas Panx1 channels
are insensitive to external Ca2þ (28), suggesting that reduction of
[Ca2þ]e induces ATP release mainly through Cx43 hemichannels. In
rat spinal astrocytes, Panx1 is reportedly opened by FGF-1-induced
increase in the intracellular Ca2þ concentration (29). In present
study, however, it is unlikely that the opening of Panx1 is mediated
by Ca2þ inﬂux in Ca2þ-free ACSF. Panx1 reportedly forms a complex
with P2X7 receptors, the activation of which by a high concentra-
tion of ATP opens Panx1 (23). In the present study, P2X7 receptor
antagonists tended to inhibit the increase in purine levels in Ca2þ-
free ACSF; therefore, Panx1 channels and P2X7 receptors might be
slightly involved in ATP release in Ca2þ-free ACSF.
Asmentioned above, changing the solution caused the release of
adenine nucleotides. Mechanical stimulation reportedly opens
Cx43 hemichannels and Panx1 channels and releases ATP (30e33).
However, gap junction inhibitors had effects on purine levels in
Ca2þ-free ACSF but not in normal ACSF. Therefore, it is suggested
that the great increase in ATP release in Ca2þ-free ACSF is not
simply owing to mechanical stimulation. Mechanical stimulation
reportedly releases ATP through secretory granules (34), maxi-
anion channels (35), and mechanosensitive ion channels (36,37).
It is possible that these channels participate in ATP release induced
by solution change. Further studies are required to elucidate the
precise mechanisms underlying ATP release from astrocytes upon
changing the solution.
In this study, it is suggested that adenosine accumulation
induced by the inhibition of adenosine metabolic enzymes is due to
the release of intracellular adenosine through ENT2, whereas
adenosine accumulation evoked by reduction of [Ca2þ]e is due to
ATP release through gap junction hemichannels. Released ATP is
rapidly degraded into adenosine by a series of ecto-enzymes
including NTPDases. In isolated tissues and in vivo, this conver-
sion of ATP into adenosine might occur more rapidly. However,
under hypoxic/ischemic conditions in the CNS including the spinal
cord, it is still unclear which of these is a main pathway. Further
studies are required to elucidate the precise mechanisms under-
lying adenosine accumulation induced by hypoxia/ischemia.Conﬂict of interest
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